Dario Pasalic1, Yi Lu2, Sonia L Betancourt-Cuellar3, Nicolette Taku1, Shane M Mesko1, Alexander F Bagley1, William W Chance1, Pamela K Allen1, Chad Tang1, Mara B Antonoff4, Peter A Balter5, Reza J Mehran4, James W Welsh1, Zhongxing Liao1, Daniel Gomez1, Jeremy J Erasmus3, Quynh-Nhu Nguyen6. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 2. Department of Radiation Oncology, Ningbo Medical Center, Lihuili Eastern Hospital, Ningbo, China. 3. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. 5. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: qnnguyen@mdanderson.org.
Abstract
BACKGROUND & PURPOSE: Stereotactic ablative radiation therapy (SABR) is an emerging treatment option for patients with pulmonary metastases; identifying patients who would benefit from SABR can improve outcomes. MATERIALS & METHODS: We retrospectively analyzed local failure (LF), distant failure (DF), overall survival (OS), and toxicity in 317 patients with 406 pulmonary metastases treated with SABR in January 2006-September 2017 at a tertiary cancer center. RESULTS: Median follow-up time was 23 months. Primary adrenal, colorectal, sarcoma, or pancreatic ("less responsive") tumors led to high rates of LF. LF rates for patients with less responsive vs. responsive tumors were 4.6% vs. 1.6% at 12 months and 12.8% vs. 3.9% at 24 months (hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.11-0.73; Log-Rank P = 0.0087). A nomogram for 24-month local control was created using Cox multivariate factors (surgical history, planning target volume, primary disease site, lung lobe location). Treating patients with ≤3 pulmonary metastases vs. >3 pulmonary metastases was associated with improved 24-month (74.2% vs. 59.3%) and 48-month (47.7% vs. 35.1%) OS (HR 0.66, 95% CI 0.47-0.95; Log-Rank P = 0.043), and reduced 12-month (22.5% vs. 50.8%) and 24-month (31.8% vs. 61.4%) intrathoracic DF (HR 0.53, 95% CI 0.38-0.74; Log-Rank P < 0.0001). The most common toxicity was asymptomatic pneumonitis (14.8%). Six patients had grade 3 events (5 pneumonitis, 1 brachial plexus). CONCLUSIONS: SABR for pulmonary metastases was effective and well tolerated. Irradiating limited intrathoracic sites of disease led to improved OS and intrathoracic DM. Higher SABR doses or surgery could be considered for less radio-responsive primary tumors.
BACKGROUND & PURPOSE: Stereotactic ablative radiation therapy (SABR) is an emerging treatment option for patients with pulmonary metastases; identifying patients who would benefit from SABR can improve outcomes. MATERIALS & METHODS: We retrospectively analyzed local failure (LF), distant failure (DF), overall survival (OS), and toxicity in 317 patients with 406 pulmonary metastases treated with SABR in January 2006-September 2017 at a tertiary cancer center. RESULTS: Median follow-up time was 23 months. Primary adrenal, colorectal, sarcoma, or pancreatic ("less responsive") tumors led to high rates of LF. LF rates for patients with less responsive vs. responsive tumors were 4.6% vs. 1.6% at 12 months and 12.8% vs. 3.9% at 24 months (hazard ratio [HR] 0.29, 95% confidence interval [CI] 0.11-0.73; Log-Rank P = 0.0087). A nomogram for 24-month local control was created using Cox multivariate factors (surgical history, planning target volume, primary disease site, lung lobe location). Treating patients with ≤3 pulmonary metastases vs. >3 pulmonary metastases was associated with improved 24-month (74.2% vs. 59.3%) and 48-month (47.7% vs. 35.1%) OS (HR 0.66, 95% CI 0.47-0.95; Log-Rank P = 0.043), and reduced 12-month (22.5% vs. 50.8%) and 24-month (31.8% vs. 61.4%) intrathoracic DF (HR 0.53, 95% CI 0.38-0.74; Log-Rank P < 0.0001). The most common toxicity was asymptomatic pneumonitis (14.8%). Six patients had grade 3 events (5 pneumonitis, 1 brachial plexus). CONCLUSIONS:SABR for pulmonary metastases was effective and well tolerated. Irradiating limited intrathoracic sites of disease led to improved OS and intrathoracic DM. Higher SABR doses or surgery could be considered for less radio-responsive primary tumors.
Authors: Eline G M Steenhuis; Ivonne J H Schoenaker; Jan Willem B De Groot; Jos A Stigt; Onne Reerink; Wouter H De Vos Tot Nederveen Cappel; Henderik L Van Westreenen; Richard M Brohet Journal: J Clin Med Date: 2022-07-01 Impact factor: 4.964
Authors: Sebastian Regnery; Carolin Buchele; Fabian Weykamp; Moritz Pohl; Philipp Hoegen; Tanja Eichkorn; Thomas Held; Jonas Ristau; Carolin Rippke; Laila König; Michael Thomas; Hauke Winter; Sebastian Adeberg; Jürgen Debus; Sebastian Klüter; Juliane Hörner-Rieber Journal: Front Oncol Date: 2022-01-11 Impact factor: 6.244
Authors: Xuguang Chen; Hanbo Chen; Ian Poon; Darby Erler; Serena Badellino; Tithi Biswas; Roi Dagan; Matthew Foote; Alexander V Louie; Umberto Ricardi; Arjun Sahgal; Kristin J Redmond Journal: Cancer Med Date: 2021-08-25 Impact factor: 4.452